Usher Syndrome Market Share Analysis By DelveInsight
Usher syndrome is a group of inherited retinal degenerations, characterized by both hearing loss and vision loss that worsens over time. The hearing loss is classified as sensorineural, which means that it is caused by abnormalities of the inner ear. The loss of vision is caused by an eye disease called retinitis pigmentosa (RP), which affects the layer of light-sensitive tissue at the back of the eye (the retina). Usher syndrome is also known as deafness-retinitis pigmentosa syndrome, Graefe-Usher syndrome, Hallgren syndrome, and retinitis pigmentosa-deafness syndrome.
Three main clinical types of Usher Syndrome have been characterized as; Type 1, Type 2, and Type 3. They are distinguished on the basis of the severity of the hearing loss, the presence or absence of vestibular dysfunction, and the age of onset of retinitis pigmentosa (RP). Usher syndrome can be caused by mutations in several different genes. Mutations in at least six genes can cause.
Usher Syndrome Market Key Facts
- The prevalence of Usher Syndrome varies from country to country, historically it has been considered a rare disorder with a frequency of 1 per 25,000, however, recent European articles estimated it to be near to 1 per 6000. Usher syndrome affects one in 12,500 in Germany.
- According to NIH, “Usher syndrome affects around 4 to 17 in 100,000 people. Types 1 and 2 accounts for 90-95% of Usher syndrome in most countries. Certain genetic mutations resulting in type 1 Usher syndrome are more common among people of eastern and central European or French Acadian heritage.”
- Usher syndrome types 1 and 2 account for approximately 10 percent of all cases of moderate to profound deafness in children.
- As per DelveInsight, Usher Syndrome is more prominent in Childs as compared to Adults.
- Higher than average numbers of people with Usher syndrome have been found among Jewish people in Israel, Berlin, Germany; and other ethnicities.
- According to a study conducted by Aifa et al. Usher syndrome Type II (USH2) appears to be the commonest clinical form of the disorder in the American population, accounting for more than 50% of all USH cases.
- As per the study by Espinos C et al., in Spain, it is found that 41.6% are US type I, 46.1% type II, and in 12.3% the classification remains unclear and it has reported the prevalence around 4.2 per 100,000 for Valencia province in Spain.
DelveInsight's "Usher Syndrome Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Usher Syndrome market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The report also covers emerging drugs, current treatment practices, Usher Syndrome market shares of the individual therapies, a detailed current Usher Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Usher Syndrome Market Analysis
The Usher Syndrome market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases in the 7MM.
The Usher Syndrome market analysis section of the report helps to understand the current and forecasted Usher Syndrome market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Usher Syndrome market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Some of the key Usher Syndrome Companiesactively involved in the development of therapies include Sanofi, ProQR Therapeutics, Neurotech Pharmaceuticals, and others.Usher Syndrome Therapies covered in the report include NT-501, QR-421a, UshStat (SAR421869), and many more.
The dynamics of the Usher Syndrome market is anticipated to change in the coming years owing to the positive outcomes of some of the candidates in the developmental stage. Key players worldwide are involved in developing therapies for the Usher Syndrome that are under phase III, II, and I clinical development and hold the potential to create a significant positive shift in the Usher Syndrome market size. The launch of emerging therapies is expected during the forecast period of 2020–2030.
Usher Syndrome Epidemiology Segmentation
- Prevalent Cases of Usher Syndrome
- Age-specific Cases of Usher Syndrome
- Subtype specific Cases of Usher Syndrome
- Diagnosed and Treatable Cases of Usher Syndrome
Usher Syndrome Epidemiology Forecast
The Usher Syndrome epidemiology section covers insights about historical and current Usher Syndrome patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Usher Syndrome Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Usher Syndrome Market Share